Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Receivables (2016 - 2025)

Vycor Medical has reported Receivables over the past 16 years, most recently at $218891.0 for Q4 2025.

  • Quarterly Receivables fell 10.75% to $218891.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $218891.0 through Dec 2025, down 10.75% year-over-year, with the annual reading at $218891.0 for FY2025, 10.75% down from the prior year.
  • Receivables was $218891.0 for Q4 2025 at Vycor Medical, down from $326052.0 in the prior quarter.
  • Over five years, Receivables peaked at $326052.0 in Q3 2025 and troughed at $126096.0 in Q4 2021.
  • The 5-year median for Receivables is $213843.0 (2022), against an average of $212584.8.
  • The largest YoY upside for Receivables was 111.51% in 2021 against a maximum downside of 20.81% in 2021.
  • A 5-year view of Receivables shows it stood at $126096.0 in 2021, then rose by 23.88% to $156204.0 in 2022, then soared by 37.79% to $215231.0 in 2023, then grew by 13.95% to $245260.0 in 2024, then dropped by 10.75% to $218891.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Receivables are $218891.0 (Q4 2025), $326052.0 (Q3 2025), and $202669.0 (Q2 2025).